Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Capital Expenditures (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Capital Expenditures data on record, last reported at $962000.0 in Q3 2025.

  • For Q3 2025, Capital Expenditures rose 8645.45% year-over-year to $962000.0; the TTM value through Sep 2025 reached $1.5 million, up 169.91%, while the annual FY2024 figure was $120000.0, 98.48% down from the prior year.
  • Capital Expenditures reached $962000.0 in Q3 2025 per TNXP's latest filing, up from $527000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $6.3 million in Q3 2023 and bottomed at -$2.6 million in Q2 2023.
  • Average Capital Expenditures over 3 years is $864545.5, with a median of $108000.0 recorded in 2024.
  • Peak YoY movement for Capital Expenditures: crashed 99.83% in 2024, then surged 26450.0% in 2025.
  • A 3-year view of Capital Expenditures shows it stood at $438000.0 in 2023, then plummeted by 99.32% to $3000.0 in 2024, then soared by 31966.67% to $962000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $962000.0 in Q3 2025, $527000.0 in Q2 2025, and $6000.0 in Q1 2025.